Oncolytics Biotech® Inc. Reports Data from Randomized Phase 2 Study of REOLYSIN® in Ovarian Cancer (measured by CA125) Ovarian Cancer and Us OVARIAN CANCER and US Ovarian Cancer and Us

Blog Archives: Nov 2004 - present

#ovariancancers



Special items: Ovarian Cancer and Us blog best viewed in Firefox

Search This Blog

Monday, March 21, 2016

Oncolytics Biotech® Inc. Reports Data from Randomized Phase 2 Study of REOLYSIN® in Ovarian Cancer (measured by CA125)



press release

 Intent-to-Treat Analysis Shows Statistically Significant Reduction in Tumour Burden as Measured by CA-125


Update Highlights
Response Using CA-125 Measurements by Treatment Among all Patients
CA-125 Response
Treatment

Paclitaxel
Paclitaxel+REOLYSIN®
Total
Full Response
1 (1.85%)
5 (9.26%)
6
Partial Response
9 (16.67%)
7 (12.96%)
16
Stable Disease
3 (5.56%)
12 (22.22%)
15
Progressive Disease
0 (0.00%)
2 (3.70%)
2
Indeterminate
16 (29.63%)
13 (24.07%)
29
Not Evaluable
25 (46.30%)
15 (27.78%)
40
Total
54
54
108

0 comments :

Post a Comment

Your comments?